MedTrace Logo

Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT06683261 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-11-12

No results posted yet for this study

Summary

The goal of this observational study is to learn more about the real-world efficacy of biologics in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). All patients who are 18 years or older, who have CRSwNP and are eligible for reimbursement of a biological for the indication of CRSwNP can be included.

The main question is the efficacy of biologics in real life after 24 weeks. The main focus are patient reported outcomes measured via several questionnaires and the nasal polyp score, scored with nasal endoscopy.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
  • Chronic Rhinosinusitis (CRS)

Interventions

BIOLOGICAL

Omalizumab

biological prescribed as add-on treatment as part of the standard of care

BIOLOGICAL

Dupilumab

biological prescribed as add-on treatment as part of the standard of care

BIOLOGICAL

Mepolizumab 100 mg

biological prescribed as add-on treatment as part of the standard of care

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Peter Hellings, MD,PhD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-23
Primary Completion
2026-01-31
Completion
2026-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06683261 on ClinicalTrials.gov